All Comments by Edward Koo
- Gamma-secretase-like cleavages of Notch and beta APP are mutually exclusive in human cells.
- Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.
- Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.
- Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide.
- APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.
- Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.
- FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex.
- Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.
- Preimplantation diagnosis for early-onset Alzheimer disease caused by V717L mutation.
- Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies.
- Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice.
- Head circumference and incident Alzheimer's disease: modification by apolipoprotein E.
- Molecular neuropathology of transgenic mouse models of Down syndrome.
- Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta.
- Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease.